Clinical Trials Browser

Phase 1/2 × Other solid neoplasm × 90 days × Clear all

NCT01064648 2026-03-18

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Phase 1/2 Active not recruiting

117 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT02535312 2026-03-18

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Phase 1/2 Active not recruiting

30 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05101070 2026-03-18

aCCeleR8-001

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT05689853 2026-03-18

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT06736704 2026-03-13

SNV4818 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07300943 2026-03-13

Study in Advanced Solid Tumor Patients

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07469774 2026-03-13

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT06057922 2026-03-12

A Study YL201 in Patients With Selected Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07229638 2026-03-12

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07466160 2026-03-12

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04939610 2026-03-11

LuMIERE

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07417189 2026-03-11

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors, Adult

NCT06499350 2026-03-10

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT07459998 2026-03-10

SKB103 for Injection in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07460375 2026-03-10

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07461181 2026-03-10

A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT02285816 2026-03-09

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced/Metastatic Solid Tumours

NCT07069062 2026-03-09

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT06130553 2026-03-06

PRIMROSE

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors That Are MTAP Deficient

NCT06656390 2026-03-06

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Cancer

NCT06795412 2026-03-06

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumours

NCT07455734 2026-03-06

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor Cancer

NCT00797719 2026-03-05

Short Neoadjuvant Hemithoracic IMRT for MPM

Phase 1/2 Completed

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05951608 2026-03-05

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06667960 2026-03-05

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT04683250 2026-03-03

MARGARET

Phase 1/2 Recruiting

Other solid neoplasmThoracic

RET-altered Non Small Cell Lung Cancer

NCT05579366 2026-03-03

RAINFOL-01

Phase 1/2 Recruiting

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06685068 2026-03-03

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07446725 2026-03-03

A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor Cancer

NCT07446855 2026-03-03

PARTHENON

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumours

NCT05083481 2026-02-27

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06833008 2026-02-27

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT07436728 2026-02-27

A Study of TAK-505 in Adults With Solid Tumors

Phase 1/2 Not yet recruiting

Other solid neoplasm

Malignant Solid Tumors

NCT07441174 2026-02-27

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

GastrointestinalOther solid neoplasm

Solid Tumor Cancer

NCT04219254 2026-02-25

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT06911827 2026-02-25

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06051695 2026-02-20

EVEREST-2

Phase 1/2 Recruiting

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms

NCT07160725 2026-02-17

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumours

NCT07293754 2026-02-17

RaPTR-101

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Malignant Solid Tumor

NCT07415863 2026-02-17

Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT06885281 2026-02-13

A Study of ZL-1310 in Participants With Selected Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors

NCT03917381 2026-02-11

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT06598371 2026-02-11

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Select Advanced Solid Tumors

NCT07328217 2026-02-11

A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT07396584 2026-02-09

A Phase I/Ⅱa Study of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

Phase 1/2 Not yet recruiting

Other solid neoplasm

Solid Tumors, Adult

NCT07205718 2026-02-06

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT07392736 2026-02-06

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT07394374 2026-02-06

A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors Harboring NTRK Fusion